Ron Tilles - Chief Executive Officer and Chairman of the Board
Ron Tilles has been on the Board of Directors of Turing Pharmaceuticals since the company launched in late 2014. Mr. Tilles started his career at Merrill Lynch in 1985, then worked at several other securities firms including Nikko and Yamaichi Securities. He is a well-respected financial services executive, having made investments in a number of public and private companies in the pharmaceutical and medical device industries over the last 20 years. Mr. Tilles was one of the founders of Retrophin, Inc. (Nasdaq: RTRX). He earned his undergraduate degree from Middlebury College in Vermont and his Masters of Business Administration from Columbia University in New York.
Eve Costopoulos - Senior Vice President & General Counsel, Legal
Eve Costopoulos is General Counsel and Chief Compliance Officer at Turing Pharmaceuticals. She has over 25 years experience at major pharmaceutical companies. Eve joined Turing in 2015 from Eisai, where she managed the Audit and Compliance functions for R&D and for the Commercial function in the Americas. Before Eisai, she held various Legal and Compliance positions at Schering Plough. Eve also worked in private practice prior to moving to the pharmaceutical industry. Eve gained her Juris Doctor (JD), Law at Seton Hall University and Bachelor of Arts (BA) at Rutgers University.
Nancy Retzlaff - Chief Commercial Officer
Nancy Retzlaff is the Chief Commercial Officer at Turing Pharmaceuticals where she is responsible for Turing's commercial operations including sales, marketing, distribution and market access. Nancy is a pharmaceutical and biotechnology business professional with more than 20 years of industry experience. Her commercial experience encompasses pharmaceutical sales, marketing and business leadership roles both globally and in the United States. Ms. Retzlaff is Canadian born and started her career in the pharmaceutical industry with Bayer Healthcare in Toronto, Canada. She relocated to the United States in 2001 and has since held commercial positions of increasing responsibility at Bayer US, Schering-Plough and Pfizer. While at Pfizer Nancy held the lead commercial role for Japan, Australia, Canada and Korea as well as a global commercial development team leadership role in neurosciences. She received a Bachelor of Commerce; Marketing & General Business at the University of Saskatchewan in Canada.
Eliseo Salinas, MD, MSc - President of Research and Development
Dr. Eliseo Salinas is President of Research and Development at Turing Pharmaceuticals AG. During his 25 year career in the Pharmaceutical Industry he has conducted numerous pre-clinical and clinical programs targeting multiple disease areas. Fifteen drug programs under Dr. Salinas' direction led to drug approvals by the Food and Drug Administration and international regulatory bodies for Central Nervous System, Gastrointestinal and Renal disorders. A native of Argentina, Dr. Salinas received his medical degree from the University of Buenos Aires, performed his residency in psychiatry at the Clinique des Maladies Mentales et de l´Encéphale and his master's in pharmacology at the Pierre and Marie Curie University, both in Paris. Dr. Salinas served on the faculty of Rene Descartes University in Paris and has published scientific papers in the area of psychopharmacology and methodology of research.